Slides
Page 1
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Welcome to our FY26 AGM The meeting will begin shortly.
Page 2
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 2026 Annual General Meeting 28 October 2026
Page 3
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Acknowledgement of Country 3 We, Australian Clinical Labs Limited, would like to acknowledge the traditional Aboriginal and Torres Strait Islander Custodians of the unceded land on which we work and deliver our services. We pay our respect to Elders past and present as the holders of memories, culture and tradition and extend that respect to Aboriginal and Torres Strait Islander peoples here today. We acknowledge the multiple and complex factors impacting Aboriginal and Torres Strait Islander peoples as the original peoples of this country and value their connections to the land, sea and community.
Page 4
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Introduction 4 Christine Bartlett Independent Non- Executive Director Chair of People and Culture Committee Mark Haberlin Independent Non- Executive Director Chair of Audit and Risk Committee Sarah Butler Independent Non- Executive Director Dr Amandeep Hansra Independent Non- Executive Director Stephen Roche Board Chair Greg Horan Group CEO & Executive Director
Page 5
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Introduction 5 Matthew Cordingley Chief Financial Officer Eleanor Padman Company Secretary Ben Powers Pitcher Partners
Page 6
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Shareholder Information How to vote: • Register by clicking on the “Get a Voting Card” button • Click “For”, “Against” or “Abstain” for each resolution • Once you have finished voting on all resolutions, please click “Submit Vote” 6
Page 7
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Shareholder Information How to ask a question • Click on the “Ask a Question” button • Fill in the box and then click submit question 7
Page 8
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Agenda 8 1. Acknowledgement of Country 2. Chair’s Address 3. CEO’s Address 4. Formal business of the meeting including Q&A
Page 9
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Chair’s Address Stephen Roche Board Chair
Page 10
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 10 FY26 Highlights ACL delivered a resilient financial performance in FY26: • Underlying EBIT increased to $69.2 million • Earnings per share increased year on year by 8.5% • Return on invested capital improved to greater than 25% • Generated strong operating cash flow of $64 million • Returned $47 million to shareholders through dividends and on-market share buy-backs
Page 11
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 CEO’s Address Greg Horan Group CEO and Executive Director
Page 12
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 12 FY27 Growth & Performance Priorities 1. Disciplined Network and Contract Growth • Expand the collection centre network and secure new contracts that meet clear strategic, service and financial criteria. 2. Strategic New Business • Pursue opportunities that allow ACL to build on capabilities already within the organisation 3. Disciplined Acquisitions • Continue to assess pathology and adjacent acquisition opportunities, including those associated with SunDoctors. 4. Revenue Quality Improvement: • Improve the completeness, timeliness and quality of revenue capture – including digitised billing, upfront payments, improved recovery of non-Medicare/unfunded tests, contract pricing and continued advocacy for appropriate industry funding. 5. Furthering Operational Improvement: • Progress Lab of the Future, the National Skin Laboratory, artificial intelligence, automation, procurement initiatives and route optimisation.
Page 13
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 13 FY27 Trading Update Signs of growth in the Australian pathology market • Medicare data for the first two months of FY27 show national market volumes up 5.8% • An increase in GP attendances are flowing through to pathology referrals • ACL’s specialist pathology referrals have also increased on the prior year Reaffirmance of FY27 Guidance • Targeting revenue of $745 - $765 million and underlying EBIT of $67 - $73 million – with an expectation of being at the higher end of the guidance • This represents an implied EBIT margin of approximately 9.0 to 9.5% • The guidance incorporates: • The final increase in wages related to the gender undervaluation outcome for pathology collectors • Anticipated benefits from initiatives already underway
Page 14
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Thank you
Page 15
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Formal business of the meeting Including Q&A
Page 16
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Adoption of the remuneration report “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report of the Company for the financial year ended 30 June 2026 as disclosed in the Directors’ Report be adopted.” Resolution 1 Proxy votes received For 95.89% Open 0.47% Against 3.64% 16
Page 17
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Resolution 2 Re-election of Dr Amandeep Hansra “That Dr Amandeep Hansra, having been appointed by the Board as a Director on 1 July 2026 to fill a casual vacancy under rule 6.1(d) of the Company’s Constitution and retiring as a Director of the Company for the purposes of ASX Listing Rule 14.4 and rule 6.1(e) of the Company’s Constitution and who has consented to stand for re-election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.” Proxy votes received For 99.21% Open 0.46% Against 0.33% 17
Page 18
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 “That Ms Christine Bartlett, retiring as a Director of the Company in accordance with rules 6.1(f)(i)(A) and 6.1(g) of the Company’s Constitution and who has consented to stand for re-election (and being eligible), be re-elected as a Director of the Company in accordance with rule 6.1(i) of the Company’s Constitution.” Proxy votes received For 95.80% Open 0.47% Against 3.72% Resolution 3 Re-election of Christine Bartlett 18
Page 19
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 “That approval be given for the purposes of ASX Listing Rule 10.14, and for all other purposes, for the grant and issue of up to 359,850 Performance Rights to Mr Greg Horan, Chief Executive Officer and Executive Director of the Company, in relation to his LTVR for FY27, in accordance with the LTVR Plan and on the terms and conditions described in the explanatory memorandum accompanying this Notice of Meeting” Proxy votes received For 98.00% Open 0.47% Against 1.52% Resolution 4 Approval of grant and issue of performance rights to Greg Horan 19
Page 20
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 “That the Proportional Takeover Provisions contained in rule 14 of the Company’s Constitution, having expired on 22 October 2026, be reinserted for a period of three years commencing on the date this resolution is passed” Proxy votes received For 99.23% Open 0.48% Against 0.28% Resolution 5 Reinsertion of proportional takeover provisions in the Constitution 20
Page 21
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 “That, for the purposes of sections 327B(1) Corporations Act 2001 and for all other purposes, Deloitte Touche Tohmatsu, having been nominated by a shareholder pursuant to section 328B Corporations Act 2001, and being qualified and having consented in writing to act as to auditor of the Company pursuant to section 328A Corporations Act 2001, be appointed as auditor of the Company to hold office from the conclusion of the Company’s 2026 AGM on 28 October 2026 until the date of its resignation or removal from the office of auditor the Company ” Proxy votes received For 99.48% Open 0.49% Against 0.03% Resolution 6 Appointment of Deloitte as new auditor 21
Page 22
129 56 193 153 153 153 255 133 0 75 75 75 226 206 242 169 121 213 Text boxes CAGR 255 188 0 112 48 160 Thank you and goodbye